Commentary

Evaluating the impact of FDA’s pregnancy and lactation labeling rule


 

Dr. Chambers is a professor of pediatrics and director of clinical research at Rady Children’s Hospital, and associate director of the Clinical and Translational Research Institute at the University of California, San Diego. She is director of MotherToBaby California, a past president of the Organization of Teratology Information Specialists, and past president of the Teratology Society. She has no relevant financial disclosures. To comment, e-mail her at obnews@frontlinemedcom.com.

Pages

Recommended Reading

VIDEO: Longer period of postpartum thromboembolic risk raises therapeutic questions
MDedge Neurology
VIDEO: Oocyte modification might prevent mitochondrial diseases
MDedge Neurology
FDA panel considers human studies of modified oocytes for preventing disease
MDedge Neurology
A brief scale IDs sleep-disordered breathing in pregnancy
MDedge Neurology
Maternal infections associated with increased risk of cerebral palsy
MDedge Neurology
Levetiracetam found effective in controlling seizures in pregnancy
MDedge Neurology
Birth registry data demonstrate familial cerebral palsy risk
MDedge Neurology
Maternal weight before pregnancy linked to children’s cognition
MDedge Neurology
Topiramate
MDedge Neurology
FDA issues new pregnancy/lactation drug label standards
MDedge Neurology

Related Articles